HC Wainwright Reiterates Buy Rating for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $55.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 88.74% from the stock’s current price. HC Wainwright also issued estimates for TG Therapeutics’ FY2025 earnings at $1.26 EPS.

Several other equities research analysts have also issued reports on the stock. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Finally, StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Stock Down 3.4 %

TGTX stock opened at $29.14 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market capitalization of $4.54 billion, a P/E ratio of -291.37 and a beta of 2.24. TG Therapeutics has a fifty-two week low of $12.84 and a fifty-two week high of $36.84. The business has a 50-day moving average of $31.69 and a 200-day moving average of $25.63.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same period last year, the company earned $0.73 EPS. The company’s revenue was down 49.4% compared to the same quarter last year. On average, sell-side analysts anticipate that TG Therapeutics will post 0.07 earnings per share for the current fiscal year.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TGTX. NBC Securities Inc. lifted its position in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares during the period. Blue Trust Inc. lifted its position in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the period. ORG Wealth Partners LLC acquired a new stake in TG Therapeutics during the third quarter worth about $53,000. Values First Advisors Inc. bought a new position in TG Therapeutics in the 3rd quarter valued at about $58,000. Finally, GAMMA Investing LLC raised its position in shares of TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 2,171 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.